The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC) - PubMed

Review

The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC)

Timothy D Wagner et al. Curr Drug Targets. 2010 Jan.

Abstract

Approximately one out of every three patients with non-small cell lung cancer (NSCLC) has locally advanced disease that is surgically unresectable. If their performance status allows, it is current practice to treat these patients with a combination of chemotherapy and external beam irradiation. There have been several studies supporting the addition of chemotherapy to radiation, particularly when delivered concurrently. There is debate over which treatment agents and schedules are most optimal, even with the most proven treatments delivering only modest results, with high rates of local and distant disease failure. Advances in imaging and radiation planning and delivery technology have allowed for the potential for improvement of the therapeutic ratio by reducing normal tissue exposure and ensuring for more precise delivery, while new systemic agents show promising activity in NSCLC. Pemetrexed is a pyrrolopyrimidine-based folate anti-metabolite that works by inhibiting a variety of enzymes of thymidylate and purine synthesis, thus leading to cell stasis and death. Similar to other cytotoxic antifolates, pemetrexed has been shown in pre-clinical study to act as an effective radiosensitizer. At present, it is being studied in phase I and II studies when combined with other systemic agents and radiation therapy in the treatment of locally advanced NSCLC, and the results have been promising. It has the advantage of allowing for relatively safe delivery of full systemic doses when combined other agents and radiation therapy, a distinction over combined modality treatments. Its efficacy, particularly in non-squamous NSCLC, in phase I and II studies has lead to investigations in the phase III setting where a more defined role for pemetrexed in locally advanced non-squamous NSCLC will potentially be defined. This review summarizes the use of combined modality treatment in locally advanced NSCLC, outlines recent advances in radiation planning and treatment, and reviews the current data on the use concurrent chemoradiation regimens featuring pemetrexed.

Similar articles

• A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.

  Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. Seiwert TY, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22. doi: 10.1158/1078-0432.CCR-06-1058. Clin Cancer Res. 2007. PMID: 17255273 Clinical Trial.

• Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

  Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, Garst J, Brotherton T, Vokes EE. Govindan R, et al. J Clin Oncol. 2011 Aug 10;29(23):3120-5. doi: 10.1200/JCO.2010.33.4979. Epub 2011 Jul 11. J Clin Oncol. 2011. PMID: 21747084 Free PMC article. Clinical Trial.

• The role of pemetrexed combined with targeted agents for non-small cell lung cancer.

  Konopa K, Jassem J. Konopa K, et al. Curr Drug Targets. 2010 Jan;11(1):2-11. doi: 10.2174/138945010790030965. Curr Drug Targets. 2010. PMID: 19839932 Review.

• Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.

  Shen X, Denittis A, Werner-Wasik M, Axelrod R, Gilman P, Meyer T, Treat J, Curran WJ, Machtay M. Shen X, et al. Radiat Oncol. 2011 Feb 16;6:17. doi: 10.1186/1748-717X-6-17. Radiat Oncol. 2011. PMID: 21324160 Free PMC article. Clinical Trial.

• Role of pemetrexed and platinums combination in patients with non-small cell lung cancer.

  Chen M, Shao W, He J, Wang D. Chen M, et al. Curr Drug Targets. 2010 Jan;11(1):29-36. doi: 10.2174/138945010790031027. Curr Drug Targets. 2010. PMID: 19839930 Review.

Cited by

• Acoustically-Activated Liposomal Nanocarriers to Mitigate the Side Effects of Conventional Chemotherapy with a Focus on Emulsion-Liposomes.

  Zafar MN, Abuwatfa WH, Husseini GA. Zafar MN, et al. Pharmaceutics. 2023 Jan 27;15(2):421. doi: 10.3390/pharmaceutics15020421. Pharmaceutics. 2023. PMID: 36839744 Free PMC article. Review.

• Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy.

  Yu X, Li J, Zhong X, He J. Yu X, et al. BMC Cancer. 2015 Oct 6;15:656. doi: 10.1186/s12885-015-1657-3. BMC Cancer. 2015. PMID: 26445227 Free PMC article. Clinical Trial.

• The Phenoxyphenol Compound 4-HPPP Selectively Induces Antiproliferation Effects and Apoptosis in Human Lung Cancer Cells through Aneupolyploidization and ATR DNA Repair Signaling.

  Liu W, Wu CY, Lu MJ, Chuang YJ, Tsai EM, Leu S, Lin IL, Ko CJ, Chiu CC, Chang WT. Liu W, et al. Oxid Med Cell Longev. 2020 Jan 7;2020:5167292. doi: 10.1155/2020/5167292. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32089770 Free PMC article.

• BPIQ, a novel synthetic quinoline derivative, inhibits growth and induces mitochondrial apoptosis of lung cancer cells in vitro and in zebrafish xenograft model.

  Chiu CC, Chou HL, Chen BH, Chang KF, Tseng CH, Fong Y, Fu TF, Chang HW, Wu CY, Tsai EM, Lin SR, Chen YL. Chiu CC, et al. BMC Cancer. 2015 Dec 16;15:962. doi: 10.1186/s12885-015-1970-x. BMC Cancer. 2015. PMID: 26672745 Free PMC article.

• ¹²⁵I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy: a comparison with best supportive care.

  Song J, Fan X, Zhao Z, Chen M, Chen W, Wu F, Zhang D, Chen L, Tu J, Ji J. Song J, et al. Onco Targets Ther. 2017 Mar 2;10:1345-1352. doi: 10.2147/OTT.S129903. eCollection 2017. Onco Targets Ther. 2017. PMID: 28280369 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ingenta plc

• Medical

  • MedlinePlus Health Information